TO THE EDITOR
There has been a controversy about the prognostic impact of myeloid antigens (MyAgs) in ALL. The issue has now regained significance since an anti-CD33 monoclonal antibody (mAb) is available for clinical treatment, which is considered for AML as well as for CD33 pos ALL. [1] [2] [3] We evaluated the prognostic impact of MyAgs in uniformly treated patients. From 9/1996 to 10/2002, 343 children with ALL were enrolled in a Czech nationwide study ALL-BFM95. In 327 patients (96%) immunophenotyping and molecular genetics were performed centrally in our reference labs. Prednisone good responders (PGR) with WBC at diagnosis o20000/mL and age 1-5 years were assigned into standard risk group (SRG). High RG (HRG) corresponded to prednisone poor response (PPR) or no remission at day 33 or BCR/ABL or MLL/AF4 fusions. The remaining patients were in the intermediate RG (IRG) . Full statistics details are in the Supplementary Information.
Immunophenotyping was performed on bone marrow (BM) samples at diagnosis on flow cytometry (FC) using FACSCalibur (BD San Jose, CA, USA). Informed consent was obtained from the patients and/or their guardians. A standard panel of mAbs was used for FC immunodiagnostics, including: CD13 (SJ1D1 Immunotech, only in B-cell precursor (BCP) ALL), CD15 (MMA BD), CD33 (D3HL60.251 Immunotech) and CD65 (88H7 Immunotech), unvaryingly throughout the study.
In a multivariate analysis of BCP ALL patients (Table 1) , CD33 was the only MyAg with an independent prognostic impact. A similar analysis on T ALL (n ¼ 45) did not show a prognostic impact of listed MyAgs, therefore, we excluded T ALL cases from further analyses. Three cases (0.92%) were excluded due to the absence of a representative leukemic population by FC and one case was excluded since CD33 was not assessed. RFS was significantly worse in BCP ALL (total ¼ 278) patients with higher CD33 pos percentage (patients with higher and lower CD33 percentage: 5-year RFS 5776 vs 8773%, median follow-up 3.3 and 4.0 years, n ¼ 98 and n ¼ 180, respectively; cutoff level: 10%; Figure 1) . A similar analysis with a cutoff level of 20% would reveal significant difference (P ¼ 0.0073, not shown). When analyzed separately by RG, this difference remains apparent and remains significant for SRG and IRG (5-year RFS in cases with lower and higher CD33 percentage, cutoff 10%: SRG, 8875 vs 59711%, n ¼ 70 and n ¼ 36, P ¼ 0.01; IRG, 9273 vs 6079%, n ¼ 88 and n ¼ 49, P ¼ 0.00073; HRG, 58713 vs 38716%, n ¼ 22 and n ¼ 13, P ¼ 0.076). The difference in IRG was significant at any cutoff level from 10 to 70% (always Po0.02, data not shown). Thus, CD33 is prognostically important especially in IRG, which is the most abundant RG among relapsed cases but patients at risk are otherwise difficult to discern. The BCP ALL cases with an intermediate percentage of CD33 pos blasts (10-50%) had a poorer outcome (5-year RFS: 6177.9%) than the CD33 neg cases (P ¼ 0.00043), but not different than the cases with high CD33 pos percentage (X50% blasts; P ¼ 0.32). The difference in the EFS of cases with higher CD33 pos cell frequency was less profound (BCP ALL: P ¼ 0.0022 and P40.05, for cutoff 10 and 20%, respectively; data not shown) compared to RFS (P ¼ 0.00002 and P ¼ 0.0073, Figure 1a ). A significant difference was noted in separate analyses for PGR (total ¼ 252), TEL/ AML1 pos (total ¼ 82) and hyperdiploid (total ¼ 62) (Po0.00001, P ¼ 0.0051 and P ¼ 0.019, respectively; Table 2 ). In PPR, we failed to prove prognostic significance of CD33 expression (P40.05, data not shown).
The striking prognostic importance of CD33 contrasts with several studies from the 1990s, 4-6 which failed to find a different prognosis of MyAg pos ALL. These papers followed a period of controversy between studies showing significantly worse prognosis of MyAg pos ALL [7] [8] [9] or no difference. 10 However, recent in vitro data showed a higher resistance for ALL blasts with MyAgs. 11 Although the aberrant MyAg expression has been known for at least 40 years, little is known about its regulation and cell biological relevance. The mechanisms that lead to the coexpression of several MyAgs in some cases are obscure; it is also not proven whether the mechanisms causing MyAg expression are comparable in T-ALL and in BCP ALL. Therefore, it is inappropriate to combine several MyAgs into composite criteria or to analyze the significance of MyAgs in BCP ALL together with T-ALL cases. A shorter follow-up is among possible reasons for a nonsignificant outcome; analysis of our data by the criteria used by Uckun et al 4 (CD33 and/or CD13 at a 30% cutoff value) does reveal a significant difference in outcome (5-year EFS 5279.2 and 7773.4%, P ¼ 0.0052, compared to 4-year EFS 7774 and 7671.8%, n.s. 4 in MyAg pos and MyAg neg BCP ALL, respectively). The median follow-up was 3.6 and 2.7 years in this and the previous 4 study, respectively. Since toxic deaths are less likely to correlate significantly with the immunophenotype, impact on RFS should always be analyzed. The difference in EFS may become insignificant when smaller cohorts of patients are analyzed. Another obscuring The independent prognostic significance of myeloid antigens (MyAgs) together with the protocol-defined risk criteria is assessed by the Cox's proportional hazard regression model. All patients in whom all listed MyAgs were investigated, n ¼ 255, are included.
variable is the difference in mAb clones used in the studyvarious mAb clones differ in the sensitivity towards the respective MyAgs. 12 This may have influenced especially multicentric analyses (Baruchel, personal communication). Therefore, it is appropriate to analyze RFS of BCP and T-ALL separately, the MyAgs should be assessed by identical mAb clones preferably in a single laboratory and the cohort should be treated by a single chemotherapy protocol. The presented population-based analysis contains all these features.
Antigen shift represents one of the possible reasons of the immunotherapy failure. Since the anti-CD33 immunotherapy is a potential extension of the presented analysis, we checked for the stability of CD33 expression at relapse. In 39 of 51 relapsed patients, we could compare the levels of CD33 expression at diagnosis and at relapse. In line with previous studies, 13 the expression among relapsed patients was rather unstable (17 of 39 switched between positivity and negativity, cutoff 20%, data not shown), and included also cases whose blasts completely lost CD33 expression at relapse. The expression of CD13 and CD15 was also unstable, contrasting with the stability of a MyAg CD66c. 14 We next asked whether a substantial shift in CD33 expression could be observed already during the induction treatment. We selected patients whose BM specimens contained at least 50% CD33 pos blasts at diagnosis. Of these, specimens were selected with a clear minimal residual disease at days 15 and/or 33 by FC. CD33 expression was ascertained with a three-color combination of CD10 (ALB2), CD33 (D3HL60.251) and CD19 (J4.119, all from Immunotech). Percentage of CD33 pos cells was assessed in gated cells according to optical scatter and CD10 and CD19 expression. The data show that despite fluctuations (Figure 1c) , most patients retain the high CD33 percentage during the induction treatment (9/12 at day 15 and 7/8 at day 33). Loss of CD33 expression thus usually does not occur at an early phase of treatment.
So far, anti-CD33 treatment in ALL has been considered only for patients with high percentage of CD33 pos blasts and no other realistic hope for cure. [1] [2] [3] The minimum percentage of CD33 pos blasts suitable for anti-CD33 immunotherapy is unknown. In the presented cohort, there are 18 patients (5.5%) who meet the arbitrary criteria of having BCP ALL with CD33 detectable on majority (greater than 50%) of blasts and being in IRG or HRG. The 5-year RFS of these patients was 40715% (the 5-year RFS of the remaining patients from the same subset was 8074%, P ¼ 0.0011). In total, eight of these patients relapsed and one developed a secondary AML. Three of them underwent allogeneic BM transplantation in second or third complete remission. Economic reckoning of anti-CD33 immunotherapy should consider that a proportion of the patients might be rescued from an intensive relapse treatment including BM transplantation. Setting the anti-CD33 immunotherapy to the induction phase of treatment seems to overcome the issue of antigen shift (Figure 1c ). In addition, peripheral nonmalignant CD33 pos cells are reduced by the intensive initial chemotherapy. This limits the risk of therapy failure due to peripheral consumption of the anti-CD33 mAb 15 and the effective dose may be lower. Clinical experience is cumulating with single anti-CD33 immunotherapy as well as in combination with chemotherapy. If the presented results are to be taken into clinical trials, a dose escalation study early during treatment is preferable to select a safe dose that does not cause a significant delay in chemotherapy but significantly reduces the leukemic clone. The fact that CD33 is not expressed on all blasts in some cases may appear a problem for the immunotherapy since CD33 neg cells may remain unaffected. However, this is not different from the contemporary treatment philosophy; most single agents can kill just a portion of the leukemic cells by themselves and the final success is achieved by combining them. Whereas standard chemotherapy targets mostly dividing cells, the suggested immunotherapy would aim at cells based on partly different characteristics. 
